Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Size: px
Start display at page:

Download "Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai"

Transcription

1 Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1

2 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there guidelines for the treatment of Parkinson s disease? 2

3 Modality of treatment Symptoms base treatment Phamacologic VS Non-phamacologic Motor VS Non-motor symptom Neuro-protective treatment Reversing pathology Prevention 3

4 Signs and Symptoms of PD Tremor at rest "Pill rolling" Rigidity (stiffness) "lead pipe" or like a "cogwheel" Akinesia (inability to move) or Bradykinesia (slow movement) mask-like face, micrographia, freezing, impaired swallowing Postural instability with gait problems Motor symptoms (TRAP) 4

5 Non-Motor Symptoms Psychological depression, psychosis, anxiety, apathy, memory problems Sleep RLS, REM behavior disorder Autonomic Dysfunction constipation, drooling, decreased BP, temp regulation Others fatigue, speech, swallowing, seborrhea, pain, weight loss) 5

6 Pathophysiology of PD and dopamine metabolism 6

7 Neurotransmitters of the Basal Ganglia Inhibitory Excitatory Dopamine Norepinephrine Epinephrine GABA Acetylcholine Serotonin Histamine Glutamate 7

8 Symptoms of PD Dopamine Ach 8

9 Symptomatic Treatment Enhance dopaminergic transmission Drug manipulating neurotransmitter Dopamine Ach 9

10 10

11 Sites of action of common therapies for Parkinson s disease Tyrosine Tyrosine L-Dopa Dopamine DA MAO-B Levodopa Increases L-Dopa levels Selegeline Inhibits MAO-B DA Degradation Amantidine Stimulates release of DA Inhibits reuptake DA Agonists Bind to DA receptors Release Binding Reuptake Degradation COMT COMT Inhibitors Block degradation of DA and L-Dopa DA Receptors Parkinson s disease Acetylcholine Inhibitors Block action of ACh in striatum 11

12 Enhance Dopaminergic transmission DA precursor Administer DA agonists Ergolides Non- ergolides Direct or indirect potentiate dopaminergic transmission Enhance DA release Block DA reuptake Inhibit DA catabolism (degradation) 12

13 Increase DA synthesis Stimulate tyrosine hydroxylase (tetrahydrobiopterin) DA precursors (tyrosine, levodopa) Modify levodopa phamacokinetic Dietary modification (minimize AA intake, asminister antacids) Block peripheral dopa decarboxylase (carbidopa, benserazide) Slow-release levodopa (sinemet CR, Madopa HBS) 13

14 Enhance DA release Amantadine Methylphetamine Dextroamphetamine Pemoline Nicotine Electroconvulsive therapy Block DA reuptake Block DA reuptake Amantadine Tricyclics Bupropion Mazidol 14

15 Inhibit DA catabolism (degradation) COMT inhibition (Tolcapone, Entacapone) MAO-B inhibitors Depreny (seligiline) Administer DA agonist Administer DA agonist Bromocryptine Pergolide Lisuride Apomorphine Pramipexole Ropinirole Cabergolide 15

16 Drug manipulating other neurotransmitter Anti-cholinergic drugs Trihexyphenidyl(Artane) Benztropine(Cogentin) Biperidine(Akineton) Orphenadrine(Disipal) Procyclidine(Kemadrine) 16

17 How to management? When to started? Drug choice? Disease progression, management and complication of treatment 17

18 Stage

19 The Natural History of Response to Levodopa in Patients With Parkinson's Disease 19

20 When to started? Interfering with activities of daily living Patient to patient Job to job 20

21 21

22 Early-anti-PD therapy L-dopa VS Dopamine agonist 22

23 Levodopa Benefit Marked improvement in the major motor signs and symptoms Virtually all PD patients response May improve mortality rate Disadvantage Cause side effect Dyskinesia and dystonia Motor fluctuation Parkinsonian psychosis Do not treat all feature of PD Do not stop disease progression Theoretically: oxidative metabolites may accelerated disease progression 23

24 Dopamine agonist Benefit Anti parkinson effect when use as mono Rx or adjunctiove Rx Reduced risk for developing L-dopa related motor complication Do not generate oxidative metabolite Levodopa sparing effect Potential neuropotential effect Disadvantage Neuropsychiatric side effect Agonist specific side effect Sedative side effect Do not treat all feature of PD Do not stop disease progression 24

25 Elderly long-term complications of L-dopa therapy minimal: short live short-term side-effects of dopamine agonists high: comorbid L-dopa as the first-line Young patient risks VS benefits: L-dopa VS dopamine agonist drugs discuss age < 65, or age > 65 with no other co-morbidity are started on dopamine agonist as initial monotherapy 25

26 Dopamine agonist 26

27 Dopamine agonist 27

28 Dopamine agonist Drug Formulation,mg Starting dose, mg Bromocriptine 2.5, daily Target dose mg/d Pergolide 0.05, 0.25, daily Pramipexole 0.125, 0.25, 0.5, 1.0, 1.5 ropinirole 0.25, 0.5, 1.0, 2.0, twice daily twice daily

29 Dopamine agonist 29

30 Levodopa Levodopa + DDI Madopar (levodopa+benserazide) Sinemet (levodopa+carbidopa) Madopar HBS Sinemet CR 30

31 Doses of the preparations of Sinemet and Madopar 31

32 How should L-dopa be started? Gradually introduced L-dopa 100 mg/day is the traditional starting dose Madopar 62.5 twice daily, or Sinemet 62.5 twice daily. (Both of these tablet formulations contain 50 mg of L-dopa.) The daily dose of L-dopa should be increased by 100 mg after 1 week same amount after 2 weeks If tolerated, further increases should be reviewed after 6 12 weeks on this dose. 32

33 L-dopa side effect 33

34 34

35 COMT: early or late Advantages No titration: easy to administer Decrease off time, increase on time Enhanced motor responses in motor fluctuation patient Reduce risk of motor complication if used from onset of levodopa therapy Disadvantage Dopaminergic side effect, esp dyskinesia Discoloration of urine Tolcapone (peripheral+central COMT) Entacapone (peripheral COMT) 35

36 36

37 Anticholinergic drugs Advantage Some antiparkinsonian efficacy Peripheral acting agent may be useful to treating sialorrhea Disadvantage Relatively ineffective for the more disabling feature of PD Cognitive side effect Troublesome muscarinic side effect 37

38 MAO-B inhibitor (selegiline) Enhance the L-dopa effect May be neuroprotective property Start 5 mg twist daily 38

39 As the disease progress, the Therapeutic window narrow symptoms and side effects occur as the levodopa therapeutic window diminishes Dyskinesia threshold Efficacy threshold Smooth, extend response Absent or infrequent dyskinesia Diminished duration Increased incidence of dykinesia Short, unpredictable response on time is associared with dyskinesia 39

40 40

41 END Thank U 41

42 Overactive Microglial Cell NO Superoxide Free Radicals Proposed Mechanisms of Dopaminergic Neuron Death in Parkinson s Disease Unknown substance releases iron from storage molecules Mutation in mitochondrial gene Unknown toxin acts on mitochondrial protein Mitochondrial complex I inhibited Loss of mitochondrial funcion NO Superoxide More Free Radicals Free radicals cause cell damage Cell Death Fe Fe + Dopamine NO [Ca 2+ ] Dopamine- Producing Cell Overactive Glutamate- Producing Cell Glu Parkinson s disease 42

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology

More information

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning

More information

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually

More information

Parkinson s Disease. Sirilak yimcharoen

Parkinson s Disease. Sirilak yimcharoen Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically

More information

10th Medicine Review Course st July Prakash Kumar

10th Medicine Review Course st July Prakash Kumar 10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS

More information

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical

More information

DRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer

DRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer DRUG TREATMENT OF PARKINSON S DISEASE Mr. D.Raju, M.pharm, Lecturer PARKINSON S DISEASE (parkinsonism) is a neurodegenerative disorder which affects t h e b a s a l g a n g l i a - and is associated with

More information

Parkinson s Disease Current Treatment Options

Parkinson s Disease Current Treatment Options Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority

More information

Drugs used in Parkinsonism

Drugs used in Parkinsonism Drugs used in Parkinsonism قادة فريق علم األدوية : لي التميمي & عبدالرحمن ذكري الشكر موصول ألعضاء الفريق املتميزين : جومانة القحطاني ندى الصومالي روان سعد القحطاني pharma436@outlook.com @pharma436 Your

More information

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS

More information

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug

More information

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease 5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater

More information

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological

More information

2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1).

2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1). Parkinson Disease 1-Parkinson disease (PD) is a chronic, progressive movement disorder resulting from loss of dopamine from the nigrostriatal tracts in the brain, and is characterized by rigidity, bradykinesia,

More information

Parkinson s Disease Medications: Professionals Edition

Parkinson s Disease Medications: Professionals Edition Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu

More information

Movement Disorders: A Brief Overview

Movement Disorders: A Brief Overview Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance

More information

Treatment of Parkinson s Disease: Present and Future

Treatment of Parkinson s Disease: Present and Future Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing

More information

Medications used to treat Parkinson s disease

Medications used to treat Parkinson s disease Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John

More information

The Shaking Palsy of 1817

The Shaking Palsy of 1817 The Shaking Palsy of 1817 A Treatment Update on Parkinson s Disease Dr Eitzaz Sadiq Neurologist CH Baragwanath Acadamic Hospital Parkinson s Disease O Premature death of dopaminergic neurons O Symptoms

More information

Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University

Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,

More information

Optimizing Clinical Communication in Parkinson s Disease:

Optimizing Clinical Communication in Parkinson s Disease: Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of

More information

Drug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)

Drug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.) Drug Management of Parkinsonism By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.) Drug management of Parkinsonism Levodopa Ergot derivatives noamine Oxidaes Inhibitors Catechol-Omethyl

More information

PARKINSON S MEDICATION

PARKINSON S MEDICATION PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development

More information

Best Medical Treatments for Parkinson s disease

Best Medical Treatments for Parkinson s disease Best Medical Treatments for Parkinson s disease Bernadette Schöneburg, M.D. June 20 th, 2015 What is Parkinson s Disease (PD)? Progressive neurologic disorder that results from the loss of specific cells

More information

Parkinson s Disease. Patients will ask you. 8/14/2015. Objectives

Parkinson s Disease. Patients will ask you. 8/14/2015. Objectives Parkinson s Disease Jean Van Kingsley MS, FNP-BC Objectives Describe the pathophysiolgy of PD. Review clinical charachteristics of PD. Identify management strategies, to maximize functional status. Recognize

More information

Evaluation and Management of Parkinson s Disease in the Older Patient

Evaluation and Management of Parkinson s Disease in the Older Patient Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of

More information

Dr Barry Snow. Neurologist Auckland District Health Board

Dr Barry Snow. Neurologist Auckland District Health Board Dr Barry Snow Neurologist Auckland District Health Board Dystonia and Parkinson s disease Barry Snow Gowers 1888: Tetanoid chorea Dystonia a movement disorder characterized by sustained or intermittent

More information

Recent Advances in the cause and treatment of Parkinson disease. Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL

Recent Advances in the cause and treatment of Parkinson disease. Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL Recent Advances in the cause and treatment of Parkinson disease Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL SOME BACKGROUND incidence rate (per 100.000 person years)

More information

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) 475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) I. General Information? Use lower doses? Start low and go slow? Expect prolonged elimination ½ lives? Expect sedative-hypnotics to be dementing, to impair cognitive

More information

PD: Key Treatment Considerations

PD: Key Treatment Considerations PD: Key Treatment Considerations 2018 Management of Neurologic and Neurosurgical Disorders in Daily Practice Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 11/27/2018 1 Outline Treatment

More information

Key Concepts and Issues in Parkinson s Disease in 2016

Key Concepts and Issues in Parkinson s Disease in 2016 Key Concepts and Issues in Parkinson s Disease in 2016 Michael Rezak, M.D., Ph.D. Section Chief, Neurosciences Institute Director, Movement Disorders and Neurodegenerative Diseases Center Northwestern

More information

Re-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.

Re-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd. Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed

More information

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000

More information

Cardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.

Cardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms. Cardinal Features of Parkinson s Management of Parkinson s Disease Kristin S. Meyer, PharmD, CGP, FASHP Assistant Professor of Pharmacy Practice Drake University & Iowa Veterans Home Spring 2009 Tremor

More information

Medication Management & Strategies When the levodopa honeymoon is over

Medication Management & Strategies When the levodopa honeymoon is over Medication Management & Strategies When the levodopa honeymoon is over Eric J Pappert, MD Parkinson s Disease & Movement Disorders Center Neurology Associates Medication Options in Parkinson s Carbidopa/Levodopa

More information

Parkinson's Disease. Robert L. Copeland, Ph.D. Howard University College of Medicine Department of Pharmacology

Parkinson's Disease. Robert L. Copeland, Ph.D. Howard University College of Medicine Department of Pharmacology Parkinson's Disease Robert L. Copeland, Ph.D. Howard University College of Medicine Department of Pharmacology 18 February 2002 Parkinson Disease Neurological disease affecting over four million patients

More information

Parkinson s Disease Update

Parkinson s Disease Update Parkinson s Disease Update Elise Anderson MD Providence Center for Parkinson s Disease October 26, 2017 11/6/2017 1 Disclosures GE Speaker, DaTSCAN 11/6/2017 2 Outline PD diagnosis Motor and nonmotor symptoms

More information

ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging. Dr. Olav E. Krigolson Lecture 5: PARKINSONS DISEASE

ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging. Dr. Olav E. Krigolson Lecture 5: PARKINSONS DISEASE ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging Dr. Olav E. Krigolson krigolson@uvic.ca Lecture 5: PARKINSONS DISEASE The Basal Ganglia Primary motor cortex Execution of movement

More information

8/28/2017. Behind the Scenes of Parkinson s Disease

8/28/2017. Behind the Scenes of Parkinson s Disease BEHIND THE SCENCES IN Parkinson s Disease Behind the Scenes of Parkinson s Disease Anna Marie Wellins DNP, ANP C Objectives Describe prevalence of Parkinson's disease (PD) Describe the hallmark pathologic

More information

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for

More information

CE on SUNDAY Newark, NJ October 18, 2009

CE on SUNDAY Newark, NJ October 18, 2009 CE on SUNDAY Newark, NJ October 18, 2009 Date: Sunday, October 18, 2009 Time: 10:30 AM 11:45 AM Location: Sheraton Newark Airport Hotel Title: Speaker(s): Treating Parkinson s Disease: A Pharmacist s Overview

More information

Parkinson s Pharmacology

Parkinson s Pharmacology PHPP 517 (IT-III) Fall 2011 JACOBS Wed 10/12 8:00 8:50 AM 1 Learning objectives 1. Describe the direct and indirect pathways of the extrapyramidal system and its modulation by ACh and DA. 2. Contrast the

More information

Objectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.

Objectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain. Objectives Emerging Treatments in Parkinson s s Disease 1) Describe recent developments in the therapies for Parkinson s Disease Jeff Kraakevik MD Assistant Professor OHSU/Portland VAMC Parkinson s Center

More information

Parkinson's Disease KP Update

Parkinson's Disease KP Update Parkinson's Disease KP Update Andrew Imbus, PA-C Neurology, Movement Disorders Kaiser Permanente, Los Angeles Medical Center No disclosures "I often say now I don't have any choice whether or not I have

More information

Margo J Nell Dept Pharmacology

Margo J Nell Dept Pharmacology Margo J Nell Dept Pharmacology 1 The extra pyramidal system Separation of cortico-spinal system (pyramidal system, (PS)) from the basal ganglia (extra pyramidal motor system (EPS)) because they produce

More information

Clinical Features and Treatment of Parkinson s Disease

Clinical Features and Treatment of Parkinson s Disease Clinical Features and Treatment of Parkinson s Disease Richard Camicioli, MD, FRCPC Cognitive and Movement Disorders Department of Medicine University of Alberta 1 Objectives To review the diagnosis and

More information

Parkinson s Disease Update. Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015

Parkinson s Disease Update. Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015 Parkinson s Disease Update Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015 Parkinson s Disease Progressive, chronic, neurodegenerative disease Slow,

More information

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing

More information

Evaluation of Parkinson s Patients and Primary Care Providers

Evaluation of Parkinson s Patients and Primary Care Providers Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,

More information

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following: 1 PARKINSON S DISEASE Parkinson's disease is a long term disease related to the central nervous system that mainly affects the motor system, resulting in the loss of dopamine, which helps in producing

More information

TRANSPARENCY COMMITTEE OPINION. 18 March 2009

TRANSPARENCY COMMITTEE OPINION. 18 March 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 March 2009 REQUIP LP 2 mg extended-release tablet Box of 21 tablets (CIP: 379 214-8) Box of 28 tablets (CIP: 379

More information

WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019

WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 YOUNG ONSET PARKINSON S DISEASE Definition: Parkinson s disease diagnosed

More information

ANTIPARKINSONIAN DRUGS. DRUGs ACT ON CNS (Pharmacology) Unit-5(8)

ANTIPARKINSONIAN DRUGS. DRUGs ACT ON CNS (Pharmacology) Unit-5(8) ANTIPARKINSONIAN DRUGS DRUGs ACT ON CNS (Pharmacology) Unit-5(8) Parkinsonism (PD) Extrapyramidal motor function disorder characterized by Rigidity Tremor Hypokinesia/Bradykinesia Impairment of postural

More information

Novel approaches to the pharmacological treatment of Parkinson s disease. Peter Jenner King s College UK

Novel approaches to the pharmacological treatment of Parkinson s disease. Peter Jenner King s College UK Novel approaches to the pharmacological treatment of Parkinson s disease Peter Jenner King s College UK Disclosures and Disclaimers Speakers fees and consultancy fees have been received from Britannia

More information

Prior Authorization with Quantity Limit Program Summary

Prior Authorization with Quantity Limit Program Summary Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.

More information

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is

More information

2/20/18. History of Parkinson s. What is happening in the brain? DOPAMINE! Epidemiology. Parkinson s Disease. It s much more than tremor

2/20/18. History of Parkinson s. What is happening in the brain? DOPAMINE! Epidemiology. Parkinson s Disease. It s much more than tremor Parkinson s Disease History of Parkinson s It s much more than tremor Laura Dixon, DNP, MPA, APRN, FNP-BC University of Louisville Department of Neurology Movement Disorders Division Parkinson s Disease

More information

XADAGO (safinamide) oral tablet

XADAGO (safinamide) oral tablet XADAGO (safinamide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage

More information

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10

More information

Parkinson's Disease and how you can make a difference with medication

Parkinson's Disease and how you can make a difference with medication Parkinson's Disease and how you can make a difference with medication Alyson Franks Parkinson's and Movement Disorder Nurse Specialist Royal Hallamshire Hospital No treatment all Complementary Therapy

More information

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD Parkinson s Disease: initial diagnosis, initial treatment & non-motor features J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even

More information

The PD You Don t See: Cognitive and Non-motor Symptoms

The PD You Don t See: Cognitive and Non-motor Symptoms The PD You Don t See: Cognitive and Non-motor Symptoms Benzi M. Kluger, M.D., M.S. Associate Professor of Neurology and Psychiatry Director Movement Disorders Center University of Colorado Denver Goals

More information

Communicating About OFF Episodes With Your Doctor

Communicating About OFF Episodes With Your Doctor Communicating About OFF Episodes With Your Doctor Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom

More information

PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.

PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N. PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N. To hear the session live on: Tuesday, April 17, 2012 at 1:00 PM ET. DIAL: 1 (888) 272-8710 and

More information

Issues for Patient Discussion

Issues for Patient Discussion onmotor complications radykinesia Screening Tools asked PD micrographia eurodegeneration Designed for Use by Family Practitioners remor on-off opamine agonists tiffness depression ostural instability wearing

More information

Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle

Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non

More information

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada PARKINSON S PRIMER Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada COPYRIGHT 2017 BY SEA COURSES INC. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted

More information

Parkinson s Disease. Gillian Sare

Parkinson s Disease. Gillian Sare Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second

More information

Making Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease

Making Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease Making Every Little Bit Count: Parkinson s Disease SHP Neurobiology of Development and Disease Parkinson s Disease Initially described symptomatically by Dr. James Parkinson in 1817 in An Essay on the

More information

DRUGS THAT ACT IN THE CNS

DRUGS THAT ACT IN THE CNS DRUGS THAT ACT IN THE CNS Drugs for Neurodegenerative Diseases 2 Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 DRUGS USED IN PARKINSON S DISEASE/ B. Selegiline and rasagiline Selegiline, also called

More information

First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy"

First described by James Parkinson in his classic 1817 monograph, An Essay on the Shaking Palsy Parkinson's Disease First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy" Parkinson s disease (PD) is a neurological disorder characterized by a progressive

More information

With Time, The Pathology of PD Spreads Throughout the Brain

With Time, The Pathology of PD Spreads Throughout the Brain With Time, The Pathology of PD Spreads Throughout the Brain Braak s staging of Parkinson s disease pathology dm co sn mc hc fc 1 Hubert H. Fernandez, MD, FAAN Professor of Medicine (Neurology) Cleveland

More information

Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817.

Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817. Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817. Four (4) hallmark clinical signs: 1) Tremor: (Note -

More information

ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM

ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM 1 CONTENTS: TOPIC PAGE Introduction 3 What should you do when a PD

More information

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone

More information

Movement Disorders. Eric Kraus, MD! Neurology!

Movement Disorders. Eric Kraus, MD! Neurology! Movement Disorders Eric Kraus, MD! Neurology! Classify Bradykinesia! Tic! Myoclonus! Tremor! Dystonia! Athetosis! Chorea! Ballismus! Case 1 This 64 year-old female has had progression of a tremor over

More information

Parkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust

Parkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust n The Leeds Teaching Hospitals NHS Trust Parkinson s disease Information for patients and carers in partnership with Leeds Community Healthcare NHS Trust The symptoms of Parkinson s appear when the levels

More information

THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE

THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE J O N AT H A N S Q U I R E S, M D, F R C P C C L I N I C A L I N S T R U C T O R, UBC F AC U L T Y O F M E D I C I N E P AC I F I C P AR K I N S

More information

III./3.1. Movement disorders with akinetic rigid symptoms

III./3.1. Movement disorders with akinetic rigid symptoms III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.

More information

What s new for diagnosing and treating Parkinson s Disease?

What s new for diagnosing and treating Parkinson s Disease? What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology

More information

Enhanced Primary Care Pathway: Parkinson s Disease

Enhanced Primary Care Pathway: Parkinson s Disease Enhanced Primary Care Pathway: Parkinson s Disease 1. Focused summary of PD relevant to primary care Parkinson s Disease (PD) and Essential tremor (ET) are two of the most common movement disorders encountered

More information

Visualization and simulated animations of pathology and symptoms of Parkinson s disease

Visualization and simulated animations of pathology and symptoms of Parkinson s disease Visualization and simulated animations of pathology and symptoms of Parkinson s disease Prof. Yifan HAN Email: bctycan@ust.hk 1. Introduction 2. Biochemistry of Parkinson s disease 3. Course Design 4.

More information

Lecture 5 Skeletal muscle relaxants. Pharmacologic management of parkinsonism and other movement disorders.

Lecture 5 Skeletal muscle relaxants. Pharmacologic management of parkinsonism and other movement disorders. Lecture 5 Skeletal muscle relaxants. Pharmacologic management of parkinsonism and other movement disorders. I. SKELETAL MUSCLE RELAXANTS Skeletal muscle relaxants are pharmacologically active substances

More information

Rasagiline and Rapid Symptomatic Motor Effect in Parkinson s Disease: Review of Literature

Rasagiline and Rapid Symptomatic Motor Effect in Parkinson s Disease: Review of Literature Neurol Ther (2014) 3:41 66 DOI 10.1007/s40120-013-0014-1 REVIEW Rasagiline and Rapid Symptomatic Motor Effect in Parkinson s Disease: Review of Literature Michele Pistacchi Francesco Martinello Manuela

More information

Advanced Therapies for Motor Symptoms in PD. Matthew Boyce MD

Advanced Therapies for Motor Symptoms in PD. Matthew Boyce MD Advanced Therapies for Motor Symptoms in PD Matthew Boyce MD Medtronic Education Teva Speakers Bureau Acadia Speakers Bureau Disclosures Discuss issues in advanced PD Adjunct therapies to levo-dopa Newer

More information

Welcome and Introductions

Welcome and Introductions Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1

More information

New Medicines Committee Briefing July 2011

New Medicines Committee Briefing July 2011 New Medicines Committee Briefing July 2011 Pramipexole immediate-release (Mirapexin ) and Pramipexole modifiedrelease (Mirapexin prolonged release) for the treatment of Parkinson s Disease Pramipexole

More information

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis Chapter 20 Drugs for Degenerative Diseases of the Nervous System Slide 18 Media Directory Levadopa Animation Upper Saddle River, New Jersey 07458 All rights reserved. Alzheimer s Disease Amyotrophic Lateral

More information

Parkinson s disease: diagnosis and current management

Parkinson s disease: diagnosis and current management n DRUG REVIEW Parkinson s disease: diagnosis and current management Lucy Collins MPhil, Gemma Cummins MRCPI and Roger A Barker PhD, MRCP SPL Treatment for Parkinson s should be tailored to the needs of

More information

Semivoluntary movement (=unvoluntary)

Semivoluntary movement (=unvoluntary) EXTRAPYRAMIDAL DISORDERS = Movement disorders = Degenerative disease 1 4 types of movements: Voluntary movement Semivoluntary movement (=unvoluntary) Involuntary movement Automatic movement 2 3 Movement

More information

Neurodegenerative diseases

Neurodegenerative diseases Neurodegenerative diseases Hiwa K. Saaed, PhD Department of Pharmacology & Toxicology College of Pharmacy University of Sulaimani Hiwa.saaed@univsul.edu.iq 2018-19 Neurodegenerative diseases of the CNS

More information

Pharmacological treatment of Parkinson's disease

Pharmacological treatment of Parkinson's disease Pharmacological treatment of Parkinson's disease Joaquim Ferreira, MD, PhD Laboratory of Clinical Pharmacology and Therapeutics Faculty of Medicine University of Lisbon PD PROGRESSION DISABILITY instability

More information

Parkinson s Disease. Graham A. Glass, MD. Assistant Professor of Neurology University of California San Francisco

Parkinson s Disease. Graham A. Glass, MD. Assistant Professor of Neurology University of California San Francisco Parkinson s Disease Graham A. Glass, MD Assistant Professor of Neurology University of California San Francisco San Francisco VA Medical Center Parkinson s Disease Research, Education and Clinical Center

More information

Pal Riba, M.D., Ph.D. Department of Pharmacology and Pharmacotherapy Semmelweis University, Budapest, Hungary November 7, 2017

Pal Riba, M.D., Ph.D. Department of Pharmacology and Pharmacotherapy Semmelweis University, Budapest, Hungary November 7, 2017 Pal Riba, M.D., Ph.D. Department of Pharmacology and Pharmacotherapy Semmelweis University, Budapest, Hungary November 7, 2017 Definition of neurodegeneration Irreversible death of neurons resulting in

More information

Neurodegenerative Disease. April 12, Cunningham. Department of Neurosciences

Neurodegenerative Disease. April 12, Cunningham. Department of Neurosciences Neurodegenerative Disease April 12, 2017 Cunningham Department of Neurosciences NEURODEGENERATIVE DISEASE Any of a group of hereditary and sporadic conditions characterized by progressive dysfunction,

More information

Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product

Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review:

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro ) (No: 289/06) Schwarz Pharma Ltd. 7 July 2006 The Scottish Medicines Consortium

More information

Drug treatment of early Parkinson s disease (motor symptoms)

Drug treatment of early Parkinson s disease (motor symptoms) 5 Drug treatment of early Parkinson s disease (motor symptoms) 5.1 When should treatment be started for a patient with Parkinson s disease? 67 5.2 Are there guidelines for the treatment of Parkinson s

More information

Understanding Parkinson s Disease Important information for you and your loved ones

Understanding Parkinson s Disease Important information for you and your loved ones Patient Education Understanding Parkinson s Disease Important information for you and your loved ones This handout explains the signs, symptoms, and possible treatments of Parkinson s disease. Parkinson

More information

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Pharmacy Coverage Guidelines are subject to change as new information becomes available. ZELAPAR (selegiline hydrochloride) orally disintegrating tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information